Making clozapine safer: current perspectives on improving its tolerability

References

• 1 Essali A, Al-Haj HN, Li C, Rathbone J. Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database Syst. Rev. 1, CD000059 (2009).
  Google Scholar
• 2 Asenjo LC, Komossa K, Rummel-Kluge C et al. Clozapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst. Rev. 11, CD006633 (2010).
  Google Scholar
• 3 Leucht S, Cipriani A, Spineli L et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 382(9896), 951–962 (2014).
  Google Scholar
• 4 Krakowski MI, Czobor P, Citrome L, Bark N, Cooper TB. Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. Arch. Gen. Psychiatry 63(6), 622–629 (2006).
  Medline CASGoogle Scholar
• 5 Tiihonen J, Lonnqvist J, Wahlbeck K et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 374(9690), 620–627 (2009).
  MedlineGoogle Scholar
• 6 Meltzer HY, Alphs L, Green AI et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch. Gen. Psychiatry 60(1), 82–91 (2003).
  Medline CASGoogle Scholar
• 7 National Collaborating Centre for Mental Health. Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Adults in Primary and Secondary Care. British Psychological Society, Leicester, UK (2009).
  Google Scholar
• 8 Meltzer HY. Treatment-resistant schizophrenia – the role of clozapine. Curr. Med. Res. Opin. 14(1), 1–20 (1997).
  Medline CASGoogle Scholar
• 9 Downs J, Zinkler M. Clozapine: national review of postcode prescribing. Psychiatrist 31, 384–387 (2007).
  Google Scholar
• 10 Howes OD, Vergunst F, Gee S, McGuire P, Kapur S, Taylor D. Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation. Br. J. Psychiatry 201(6), 481–485 (2012).
  MedlineGoogle Scholar
• 11 Ciapparelli A, Dell’Osso L, Pini S, Chiavacci MC, Fenzi M, Cassano GB. Clozapine for treatment-refractory schizophrenia, schizoaffective disorder, and psychotic bipolar disorder: a 24-month naturalistic study. J. Clin. Psychiatry 61(5), 329–334 (2000).
  Medline CASGoogle Scholar
• 12 Taylor DM, Douglas-Hall P, Olofinjana B, Whiskey E, Thomas A. Reasons for discontinuing clozapine: matched, case-control comparison with risperidone long-acting injection. Br. J. Psychiatry 194(2), 165–167 (2009).
  MedlineGoogle Scholar
• 13 Waserman J, Criollo M. Subjective experiences of clozapine treatment by patients with chronic schizophrenia. Psychiatr. Serv. 51(5), 666–668 (2000).
  Medline CASGoogle Scholar
• 14 Whiskey E, Olofinjana O, Taylor D. The importance of the recognition of benign ethnic neutropenia in black patients during treatment with clozapine: case reports and database study. J. Psychopharmacol. 25(6), 842–845 (2011).
  Medline CASGoogle Scholar
• 15 Taylor D, Shapland L, Laverick G, Bond J, Munro J. Clozapine- a survey of patient perceptions. Psychiatrist 2000;(24):450–452.
  Google Scholar
• 16 Gee S, Vergunst F, Howes O, Taylor D. Practitioner attitudes to clozapine initiation. Acta. Psychiatr. Scand. doi:10.1111/acps.12193 (2013) (Epub ahead of print).
  MedlineGoogle Scholar
• 17 Rocha FL, Hara C. Benefits of combining aripiprazole to clozapine: three case reports. Prog. Neuropsychopharmacol. Biol. Psychiatry 30(6), 1167–1169 (2006).
  Medline CASGoogle Scholar
• 18 Pisani F, Oteri G, Costa C, Di RG, Di PR. Effects of psychotropic drugs on seizure threshold. Drug Saf. 25(2), 91–110 (2002).
  Medline CASGoogle Scholar
• 19 Ronaldson KJ, Fitzgerald PB, Taylor AJ, Topliss DJ, Wolfe R, McNeil JJ. Rapid clozapine dose titration and concomitant sodium valproate increase the risk of myocarditis with clozapine: a case-control study. Schizophr. Res. 141(2–3), 173–178 (2012).
  MedlineGoogle Scholar
• 20 Syed R, Au K, Cahill C et al. Pharmacological interventions for clozapine-induced hypersalivation. Cochrane Database Syst. Rev. 3, CD005579 (2008).
  Google Scholar
• 21 Schneider B, Weigmann H, Hiemke C, Weber B, Fritze J. Reduction of clozapine-induced hypersalivation by pirenzepine is safe. Pharmacopsychiatry 37(2), 43–45 (2004).
  Medline CASGoogle Scholar
• 22 Bai YM, Lin CC, Chen JY, Liu WC. Therapeutic effect of pirenzepine for clozapine-induced hypersalivation: a randomized, double-blind, placebo-controlled, cross-over study. J. Clin. Psychopharmacol. 21(6), 608–611 (2001).
  Medline CASGoogle Scholar
• 23 Kreinin A, Novitski D, Weizman A. Amisulpiride treatment of clozapine-induced hypersalivation in schizophrenia patients: a randomised, double-blind, placebo-controlled cross-over study. Int. Clin. Psychopharmacol. 21(2), 99–103 (2006).
  MedlineGoogle Scholar
• 24 Wang J, Omori IM, Fenton M, Soares B. Sulpiride augmentation for schizophrenia. Cochrane Database Syst. Rev. 1, CD008125 (2010).
  Google Scholar
• 25 Reinstein M, Sirotovskaya L, Chasanov M, Jones L, Mohan S. Comparative efficacy and tolerability of benztropine and terazosin in the treatment of hypersalivation secondary to clozapine. Clin. Drug Invest. 17(2), 97–106 (1999).
  CASGoogle Scholar
• 26 Palmer SE, McLean RM, Ellis PM, Harrison-Woolrych M. Life-threatening clozapine-induced gastrointestinal hypomotility: an analysis of 102 cases. J. Clin. Psychiatry 69(5), 759–768 (2008).
  Medline CASGoogle Scholar
• 27 Gugger JJ. Antipsychotic pharmacotherapy and orthostatic hypotension: identification and management. CNS Drugs 25(8), 659–671 (2011).
  Medline CASGoogle Scholar
• 28 Testani M Jr. Clozapine-induced orthostatic hypotension treated with fludrocortisone. J. Clin. Psychiatry 55(11), 497–498 (1994).
  MedlineGoogle Scholar
• 29 Ronaldson KJ, Fitzgerald PB, Taylor AJ, Topliss DJ, McNeil JJ. A new monitoring protocol for clozapine-induced myocarditis based on an analysis of 75 cases and 94 controls. Aust. NZ J. Psychiatry 45(6), 458–465 (2011).
  MedlineGoogle Scholar
• 30 Sulfi S, Timmis AD. Ivabradine – the first selective sinus node I(f) channel inhibitor in the treatment of stable angina. Int. J. Clin. Pract. 60(2), 222–228 (2006).
  Medline CASGoogle Scholar
• 31 Lally J, Brook J, Dixon T et al. Ivabradine, a novel treatment for clozapine induced sinus tachycardia: a case series. Ther. Adv. Psychopharmacol. doi:10.1177/2045125313512325 (2013) (Epub ahead of print).
  Google Scholar
• 32 La GL, Graham D, Trontell A. Myocarditis and cardiomyopathy associated with clozapine use in the United States. N. Engl. J. Med. 345(3), 224–225 (2001).
  MedlineGoogle Scholar
• 33 Warner B, Alphs L, Schaedelin J, Koestler T. Clozapine and sudden death. Lancet 355(9206), 842 (2000).
  Medline CASGoogle Scholar
• 34 Kilian JG, Kerr K, Lawrence C, Celermajer DS. Myocarditis and cardiomyopathy associated with clozapine. Lancet 354(9193), 1841–1845 (1999).
  Medline CASGoogle Scholar
• 35 Leo RJ, Kreeger JL, Kim KY. Cardiomyopathy associated with clozapine. Ann. Pharmacother. 30(6), 603–605 (1996).
  Medline CASGoogle Scholar
• 36 Layland JJ, Liew D, Prior DL. Clozapine-induced cardiotoxicity: a clinical update. Med. J. Aust. 190(4), 190–192 (2009).
  MedlineGoogle Scholar
• 37 Covell NH, Weissman EM, Essock SM. Weight gain with clozapine compared with first generation antipsychotic medications. Schizophr. Bull. 30(2), 229–240 (2004).
  MedlineGoogle Scholar
• 38 Menza M, Vreeland B, Minsky S, Gara M, Radler DR, Sakowitz M. Managing atypical antipsychotic-associated weight gain: 12-month data on a multimodal weight control program. J. Clin. Psychiatry 65(4), 471–477 (2004).
  MedlineGoogle Scholar
• 39 Vreeland B, Minsky S, Menza M, Rigassio RD, Roemheld-Hamm B, Stern R. A program for managing weight gain associated with atypical antipsychotics. Psychiatr. Serv. 54(8), 1155–1157 (2003).
  MedlineGoogle Scholar
• 40 Fleischhacker WW, Heikkinen ME, Olie JP et al. Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. Int. J. Neuropsychopharmacol. 13(8), 1115–1125 (2010).
  Medline CASGoogle Scholar
• 41 Chen CH, Huang MC, Kao CF et al. Effects of adjunctive metformin on metabolic traits in nondiabetic clozapine-treated patients with schizophrenia and the effect of metformin discontinuation on body weight: a 24-week, randomized, double-blind, placebo-controlled study. J. Clin. Psychiatry 74(5), e424–e430 (2013).
  Medline CASGoogle Scholar
• 42 Hamoui N, Kingsbury S, Anthone GJ, Crookes PF. Surgical treatment of morbid obesity in schizophrenic patients. Obes. Surg. 14(3), 349–352 (2004).
  MedlineGoogle Scholar
• 43 Henderson DC, Cagliero E, Gray C et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. Am. J. Psychiatry 157(6), 975–981 (2000).
  Medline CASGoogle Scholar
• 44 Ojala K, Repo-Tiihonen E, Tiihonen J, Niskanen L. Statins are effective in treating dyslipidemia among psychiatric patients using second-generation antipsychotic agents. J. Psychopharmacol. 22(1), 33–38 (2008).
  Medline CASGoogle Scholar
• 45 Caniato RN, Alvarenga ME, Garcia-Alcaraz MA. Effect of omega-3 fatty acids on the lipid profile of patients taking clozapine. Aust. NZ J. Psychiatry 40(8), 691–697 (2006).
  MedlineGoogle Scholar
• 46 Taylor D, Paton C, Kapur S. The Maudsley Prescribing Guidelines in Psychiatry (11th Edition). Wiley-Blackwell, West Sussex, UK, 95 (2012).
  Google Scholar
• 47 Munro J, O’Sullivan D, Andrews C, Arana A, Mortimer A, Kerwin R. Active monitoring of 12,760 clozapine recipients in the UK and Ireland. Beyond pharmacovigilance. Br. J. Psychiatry 175, 576–580 (1999).
  Medline CASGoogle Scholar
• 48 Dunk LR, Annan LJ, Andrews CD. Rechallenge with clozapine following leucopenia or neutropenia during previous therapy. Br. J. Psychiatry 188, 255–263 (2006).
  MedlineGoogle Scholar
• 49 Andres E, Zimmer J, Affenberger S, Federici L, Alt M, Maloisel F. Idiosyncratic drug-induced agranulocytosis: update of an old disorder. Eur. J. Intern. Med. 17(8), 529–535 (2006).
  Medline CASGoogle Scholar
• 50 Cohen D, Bogers JP, van Dijk D, Bakker B, Schulte PF. Beyond white cell monitoring: screening in the initial phase of clozapine therapy. J. Clin. Psychiatry 73(10), 1307–1312 (2012).
  Medline CASGoogle Scholar
• 51 Manu P, Sarpal D, Muir O, Kane JM, Correll CU. When can patients with potentially life-threatening adverse effects be rechallenged with clozapine? A systematic review of the published literature. Schizophr. Res. 134(2–3), 180–186 (2012).
  MedlineGoogle Scholar
• 52 Haddy TB, Rana SR, Castro O. Benign ethnic neutropenia: what is a normal absolute neutrophil count? J. Lab. Clin. Med. 133, 15–22 (1999).
  Medline CASGoogle Scholar
• 53 Adityanjee. Modification of clozapine-induced leukopenia and neutropenia with lithium carbonate. Am. J. Psychiatry 152(4), 648–649 (1995).
  MedlineGoogle Scholar
• 54 Blier P, Slater S, Measham T, Koch M, Wiviott G. Lithium and clozapine-induced neutropenia/agranulocytosis. Int. Clin. Psychopharmacol. 13(3), 137–140 (1998).
  Medline CASGoogle Scholar
• 55 Silverstone PH. Prevention of clozapine-induced neutropenia by pretreatment with lithium. J. Clin. Psychopharmacol. 18(1), 86–88 (1998).
  Medline CASGoogle Scholar
• 56 Whiskey E, Taylor D. Restarting clozapine after neutropenia: evaluating the possibilities and practicalities. CNS Drugs 21(1), 25–35 (2007).
  Medline CASGoogle Scholar
• 57 Pui-yin CJ, Shiu-yin CC, Chung KF, Lai-wah DE, Wai-nang TO, Chan WF. The incidence and characteristics of clozapine-induced fever in a local psychiatric unit in Hong Kong. Can. J. Psychiatry 53(12), 857–862 (2008).
  MedlineGoogle Scholar
• 58 Jeong SH, Kim JH, Ahn YM et al. A 2-year prospective follow-up study of lower urinary tract symptoms in patients treated with clozapine. J. Clin. Psychopharmacol. 28(6), 618–624 (2008).
  Medline CASGoogle Scholar
• 59 Steingard S. Use of desmopressin to treat clozapine-induced nocturnal enuresis. J. Clin. Psychiatry 55(7), 315–316 (1994).
  Medline CASGoogle Scholar
• 60 Lurie SN, Hosmer C. Oxybutynin and intranasal desmopressin for clozapine-induced urinary incontinence. J. Clin. Psychiatry 58(9), 404 (1997).
  Medline CASGoogle Scholar
• 61 McCabe JH, Travis M. Clozapine induced obsessive compulsive symptoms. Prog. Neuropsychopharmacol. Biol. Psychiatry 28(7), 1209 (2004).
  MedlineGoogle Scholar
• 62 Englisch S, Zink M. Treatment-resistant schizophrenia: evidence-based strategies. Mens. Sana Monogr. 10(1), 20–32 (2012).
  MedlineGoogle Scholar
• 63 Englisch S, Esslinger C, Inta D et al. Clozapine-induced obsessive–compulsive syndromes improve in combination with aripiprazole. Clin. Neuropharmacol. 32(4), 227–229 (2009).
  Medline CASGoogle Scholar
• 64 Nielsen J, Dahm M, Lublin H, Taylor D. Psychiatrists’ attitude towards and knowledge of clozapine treatment. J Psychopharmacol 24(7), 965–971 (2010).
  Medline CASGoogle Scholar
• 65 Mistry H, Osborn D. Underuse of clozapine in treatment-resistant schizophrenia. Adv. Psychiatr. Treat. 17, 250–255 (2011).
  Google Scholar